SCHEMBL6765430

SCHEMBL6765430

Nc1ccn([C@@H]2O[C@H](COC(=O)c3ccccc3)[C@@H](OC(=O)c3ccccc3)[C@H]2OC(=O)c2ccccc2)c(=O)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.59
USP2 O75604 1/20 0.59
POLB P06746 1/20 0.59
KMT2A Q03164 1/20 0.59
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
GAPDH P04406 2/20 0.51
ALDH1A1 P00352 2/20 0.49
LMNA P02545 1/20 0.49
THRB P10828 1/20 0.49
MTOR P42345 1/20 0.49
MDM2 Q00987 1/20 0.49
NCOA1 Q15788 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49
ST6GAL1 P15907 4/20 0.47
HRAS P01112 1/20 0.46
P2RX3 P56373 1/20 0.46
P2RX4 Q99571 1/20 0.46
P2RX2 Q9UBL9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14011209 1.00 MEN1 (0.59) MEN1USP2POLBKMT2ACA1
SCHEMBL8516844 1.00 MEN1 (0.59) MEN1USP2POLBKMT2ACA1
Hydrochloric Acid SCHEMBL11628090 0.99 MEN1 (0.58) MEN1USP2POLBKMT2ACA1
SCHEMBL19594242 0.92 MEN1 (0.53) MEN1USP2POLBKMT2ACA1
SCHEMBL28197797 0.92 LMNA (0.55) MEN1USP2POLBKMT2ACA1
SCHEMBL4570558 0.91 MEN1 (0.52) MEN1USP2POLBKMT2ACA1
SCHEMBL18271847 0.91 MEN1 (0.54) MEN1USP2POLBKMT2ACA1
SCHEMBL26647521 0.91 MEN1 (0.52) MEN1USP2POLBKMT2ACA1
SCHEMBL16556343 0.91 MEN1 (0.52) MEN1USP2POLBKMT2ACA1
SCHEMBL9069024 0.90 KMT2A (0.52) MEN1USP2POLBKMT2ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 US disclosed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 US disclosed
EP-0003229-B1 METHOD FOR THE PREPARATION OF NUCLEOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 1981-12-02 EP disclosed
US-4209613-A Process for the preparation of nucleosides SCHERING AKTIENGESELLSCHAFT (DE) 1980-06-24 US disclosed
EP-0003229-A1 Method for the preparation of nucleosides SCHERING AKTIENGESELLSCHAFT (DE) 1979-08-08 EP disclosed
US-4082911-A PROCESS FOR THE PREPARATION OF NUCLEOSIDES SCHERING AKTIENGESELLSCHAFT (DT) 1978-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008841-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 MEN1 4883/4885USP2 3286/4885POLB 690/4885
US-20040110718-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 MEN1 4883/4885USP2 3286/4885POLB 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.